gg2
New COVID vaccines
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
FDA approved four new COVID-19 vaccines for fall 2026-27. The shots target the XFG variant but are restricted to high-risk groups.
Background
The FDA authorized new formulations of COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi on August 27, 2026. These vaccines are designed to better match currently circulating variants, particularly the XFG variant. However, they are initially approved only for adults over 65 and younger people with chronic conditions, with others potentially eligible off-label.
How it unfolded
- Aug 27, 2026FDA issued letters authorizing new COVID-19 vaccine formulations from Moderna, Pfizer-BioNTech, and Novavax-Sanofi.
- Aug 31, 2026Forbes Health reported that the new vaccines provide updated protection against the XFG variant.
- Sep 1, 2026CVS Pharmacy announced it expects to receive supply of the new vaccines within a few days and will offer them to eligible patients.
- Sep 2, 2026Medical groups like ACOG issued guidance recommending vaccination for pregnant and breastfeeding individuals, filling a gap left by the CDC.
Who’s saying what
- Official
- FDA approved the vaccines to better combat circulating variants and protect high-risk populations.
- Expert
- Dr. David Cutler says the new vaccines give an 'extra layer of protection' against the circulating strain.
- Caution
- Dr. Dan Barouch notes vaccines are generally less effective in immunosuppressed individuals, who remain at higher risk.
Still unverified
Legal disputes stemming from past Trump administration actions may complicate access for some people, but details are not fully clarified.